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Background: Argon treatment following experimental neurotrauma has been found neuroprotective in an array of
in vivo and in vitro models. The inherent cellular and molecular mechanisms are still unknown. We seeked to shed
light on these processes by examinig the cellular distribution and the expression of inflammatory markers and
growth factors in argon treated brain tissue.
Methods: Male adult Sprague-Dawley rats were randomly assigned to one of the study groups: sham surgery +
placebo, sham surgery + argon, tMCAO + placebo, and tMCAO + argon. Animals underwent 2 h-transient middle
cerebral artery occlusion (tMCAO) using the endoluminal thread model or sham surgery without tMCAO. After the
first hour of tMCAO or sham surgery a 1 h inhalative argon (50% argon/50% O2) or placebo (50% N2/50% O2)
treatment was performed. Brains were removed and evaluated after 24 h. RealTime-PCR was performed from
biopsies of the penumbra and contralateral corresponding regions. Paraffin sections were immunostained with
antibodies against GFAP, NeuN, and Iba1. Cell counts of astrocytes, neurons and microglia in different cortical
regions were performed in a double-blinded manner.
Results: Fifteen animals per tMCAO group and twelve sham + placebo respectively eleven sham + argon animals
completed the interventional procedure. We identified several genes (IL-1β, IL-6, iNOS, TGF-β, and NGF) whose
transcription was elevated 24 h after the study intervention, and whose expression levels significantly differed
between argon treatment and placebo following tMCAO. Except for the core region of ischemia, cell numbers
were comparable between different treatment groups.
Conclusion: In our study, we found an elevated expression of several inflammatory markers and growth factors
following tMCAO + argon compared to tMCAO + placebo. Although conflicting the previously described
neuroprotective effects of argon following experimental ischemia, these findings might still be associated with each
other. Further studies will have to evaluate their relevance and potential relationship.
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Cerebral ischemia and its sequelae is one of the leading
causes of death and long-term disability worldwide [1,2].
In contrast to its common incidence, therapeutic options
are limited. Due to the high vulnerability of neuronal tis-
sue to oxygen deprivation, recanalization procedures have* Correspondence: mcoburn@ukaachen.de
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article, unless otherwise stated.to take place in a limited time slot of 3 h and up to 4.5 h
in special cases [1]. The area of greatest interest is the so
called penumbra: the transition zone in between ischemic
core and healthy tissue, where neurons are in a state of hi-
bernation that can be restituted ad integrum with optimum
treatment [3]. Numerous experimental therapeutic ap-
proaches have focused on protection and salvation of neu-
rons in this area. While most of these therapeutics showed
promising results in experimental studies, none to negative
effects were seen in clinical trials [1]. Until today, and withntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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has found its way into cerebral ischemia treatment
guidelines [1,2].
The noble gas argon has recently come into focus as a
potential adjunctive neuroprotective agent: protective
effects of noble gases have been widely shown in differ-
ent experimental models [4-6], and argon seems to have
similar beneficial effects on injured tissue [7-10]. More-
over, unlike xenon, it lacks sedative side effects under
normobaric conditions [11], and is cheaper due to its
higher fraction in normal atmosphere. These features
plus expectedly little disadvantageous side effects in
humans make argon a promising candidate. However,
while neuroprotective effects of argon have already been
demonstrated, data on its cellular actions are limited: In
vitro, argon activated a cellular enzyme, and it only
slightly interfered with the inflammatory microglial re-
sponse following stimulation with bacterial lipopoly-
saccharide [12]. In vivo, an elevated expression of an
anti-apoptotic protein was found elevated following
argon treatment in neonatal asphyxia [7]. Argon’s pro-
tective action was not exerted via NMDA-antagonism
by interaction with glycine in a model of traumatic
brain injury [9]. The mechanisms for argon’s neuropro-
tective actions in cerebral ischemia are unknown.
The aim of this study was to shed first light on argon’s
mechanisms of action in a stroke model. 24 h after transi-
ent middle cerebral artery occlusion (tMCAO) [13] and a
delayed additional administration of 50% argon as de-
scribed previously [10], we performed a gene expression
analysis of inflammatory and growth factors and examined
the distribution of vital neurons, microglia and astrocytes
in the penumbra.
Methods
Study design and animal enrolment
This experimental study was in part designed as a
subgroup- and follow-up analysis of the above men-
tioned efficacy analysis of argon in MCAO [10], with
additional enrolment of animals obtaining the same ex-
perimental procedures. Animal research and care proce-
dures were approved by the governmental review board
(Landesamt für Natur, Umwelt und Verbraucherschutz,
Germany) beforehand. Species-appropriate housing was
assured in macrolone cages in a specified pathogen-free
environment, with food and water ad libitum and a
12 h-light-dark-cycle.
Transient middle cerebral artery occlusion (tMCAO)
Male Sprague Dawley rats (250-295 g, Harlan Labora-
tories, Netherlands) were randomly assigned to one of
the following groups: a) sham surgery + placebo (Sham
N2): n = 12; b) sham surgery + argon treatment (Sham
Ar): n = 12; c) tMCAO + placebo (tMCAO N2): n = 15;and d) tMCAO + argon (tMCAO Ar): n = 15. One ani-
mal in the Sham Ar group was lost before completion
of the 24 h follow-up due to other than intervention-
associated reasons.
The interventional procedure is pictured in Figure 1A.
Following induction of anaesthesia (0,15 mg/kg medeto-
midine, 2 mg/kg midazolam and 0.005 mg/kg fentanyl
i.p.), animals underwent 2 h of tMCAO with the intra-
luminal thread-occlusion technique [10,13] or sham sur-
gery (identical surgical procedure without intraluminal
thread-occlusion). Full occlusion of the middle cerebral
artery (MCA) was assured by laser Doppler flowmetric
assessment of the blood flow in this vessel (PeriFlux Sys-
tem 5000, Type PF 5001, Perimed, Sweden) as previously
described [10]. Throughout the surgical procedure, ani-
mal body temperature was sustained at 37°C. Anaesthe-
sia was maintained by repeated i.p. doses of 0.1-0.15 ml
of the above described anesthetic mixture in 1 h inter-
vals, if applicable titrated to clinical needs. Heart rate,
arterial oxygen saturation and mean arterial blood pres-
sure were continuously assessed, blood gases and pH
were repeatedly measured to verify sufficient spontan-
eous breathing and circulation. At the end of the first
hour after induction of tMCAO (or sham surgery), ani-
mals were treated according to their randomization with
either placebo (nitrogen) or argon for another hour until
reperfusion [10]. Argon or placebo were applied in an
inspiratory concentration of 50% mixed with 50% oxygen
via facial mask and spontaneous ventilation of the i.p.
anesthetized animals. Sufficient ventilation was guaran-
teed by regular blood gas analyses for normoxia and nor-
mocarbia [10]. After 2 h of tMCAO including 1 h of
treatment, reperfusion was restored by removal of the
thread in the tMCAO animals. Following surgical clos-
ure of skin wounds and preemptive pain therapy (meta-
mizole 15-50 mg/kg body weight), all animals were
returned to their cages for recovery. Animals underwent
neurological and behavioral testing [10,14] directly be-
fore sacrifice at 24 h post interventionem.
Tissue preparation for gene expression analysis
Rat brains were removed immediately after sacrifice in deep
anesthesia, cut into seven 2 mm thick coronal sections
using a rat brain matrix (Plastics One Inc., USA) and
stained at 37°C for 15 min in a 2% solution of 2,3,5-triphe-
nyltetrazolium chloride (TTC) in normal saline to dis-
criminate vital from dead tissue [15,16]. Images of the
TTC-stained sections were acquired (Sony DXC 390P, Sony
Germany) before cryo-preservation at -80°C until further
processing. Infarct volumes were assessed with an image
analysis software (Optimas 6.5; Adept Electronic Solutions
Pty Ltd, Sydney, Australia). Addition of all cross-sectional
infarcted coronal brain sections which were multiplied by 2
(2 mm slice thickness) rendered the total infarct volumes of
Figure 1 Study procedure and exemplary histological graphics. A simplified graphic of the study procedure is shown in A. After
randomization animals received i.p. anesthesia and tMCAO or sham surgery. 1 h after the occlusion of the MCA with a thread treatment with 50%
argon/50% oxygen or placebo (a 50% nitrogen/oxygen-mixture) was performed by mask inhalation for another hour. After that, treatment and
MCA occlusion were terminated. Animals were left to recover from the procedure. 24 h later after behavioral testing, animals were sacrificed and
brains obtained for further experiments. Example pictures of the HE-stained penumbra regions (slice 3) from the tMCAO + argon (MCAO Ar) and
tMCAO + placebo (MCAO N2) groups vs. corresponding regions from sham + argon (Sham Ar) and sham + placebo (Sham N2) are shown in B. The
demarcation zone between penumbra and necrotic tissue is tagged with a bold black line. The interhemispheric fissure is asterisked. The positions
of the images taken for cell evaluation and quantification are marked by black rectangles (h healthy cortex; p penumbra; c ischemic core).
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corrected by use of this formula [17]:
Vedi ¼ Vinfarct 1− Vipsi−Vcontrað Þ=Vcontrað Þ
V edi = Volume edema-corrected infarct volume, V in-
farct = Volume infarct, V ipsi = Volume ipsilateral infarcted
hemisphere, V contra = Volume contralateral non-infarcted
hemisphere.RNA isolation
On the basis of TTC-staining, the penumbra regions of the
infarcted brain hemispheres were identified. Total RNA
was isolated from the cortical penumbra of the infarcted
hemisphere and corresponding contralateral regions from
three consecutive coronal sections of each brain (sections
3, 4 and 5) employing NucleoSpin RNA II (MACHEREY-
NAGEL, Germany) according to the manufacturers’ in-
structions. Briefly, brain tissue was homogenized (5000 g,
15 s) with Precellys Keramik-Kit (PEQLAB Biotechnologie,
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mercaptoethanol, filtrated by centrifugation and
washed in 70% ethanol. DNA was digested and RNA
purified in several washing steps and eluted in ultra-
purified water (Invitrogen, Germany).
Gene expression analysis
RNA concentrations and purity were measured using










Chemokine (C-C) ligand 2 CCAGAAACCAGCCAACTCTC Sense
CCL2 CCGACTCATTGGGATCATCT Antisen
Matrix metalloproteinase-9 CCACCGAGCTATCCACTCAT Sense
MMP-9 GTCCGGTTTCAGCATGTTTT Antisen
Hypoxia inducible factor 1 TCAAGTCAGCAACGTGGAAG Sense
alpha (HIF-1α) TATCGAGGCTGTGTCGACTG Antisen






















Glial fibrillary acid protein AGAAAACCGCATCACCATT Sense
(GFAP) GCACACCTCACATCACATCC Antisen
Insulin-like growth factor 1 TGATCTGAGGAGGCTGGAGATGTA Sense
IGF-1 CTTCTGAGTCTTGGGCATGTCA Antisen
A full summary of the primer sequences employed for gene expression analysis pluReverse transcription reactions were performed with M-
MLV RT-kit (Invitrogen, Germany) according to the manu-
facturer’s instructions and random hexanucleotide primers
(Invitrogen, Germany). Real-time rtPCR (RT-rtPCR) reac-
tions were carried out in a mixture containing 2 μl cDNA,
2 μl RNAse-free water (Invitrogen, Germany), 5 μl 2 × Sensi
Mix × Plus SYBR & Fluorescein Kit (Quantace, Bioline,
Germany) and 0.5 μl primers (10pmol/μl). Primer se-







60 196 82 NM_017101.1
se
57 210 85 NM_012675.3
se
60 210 81 NM_031512.2
se
60 161 78 NM_012589.1
se
59 192 83 NM_031530.1
se
60 180 79 NM_031055.1
se
60 198 81 NM_024359.1
se
60 81 78 NM_031116.3
se
63 393 88 NM_012578.2
se
60 100 82 NM_001067130.1
se
60 196 84 NM_031836.2
se
59 179 85 NM_012611.3
se
60 232 84 NM_001108140.1
se
62 219 82 NM_012711.1
se
60 257 82 M18630.1
se
60 188 83 NM_017009.2
se
59 95 82 NM_178866.4
se
s their characteristics is given in Table 1.
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(Bio-Rad Laboratories, Germany) under the following con-
ditions: 10 min enzyme activation at 95°C, 40 times 15 s de-
naturation at 95°C then 30 s annealing at individual
temperatures then 30 s amplification at 72°C, and 5 s fluor-
escence measurement at 72°C. Internal standard curves to
assess the concentration of the target gene in the samples
were generated by measuring several dilutions of a target
gene pool with each reaction. Melting curve analysis and
agarose gel electrophoretic evaluation of the RT-rtPCR
products were routinely performed to determine the speci-
ficity of the RT-rtPCR reaction. Gene expressions were nor-
malized to the mean expression values of the housekeeping
gene cyclophilin A; the expression levels of the infarctedFigure 2 Expression levels of inflammatory genes. Expression levels of
Figure 2 (A: CD3; B: CD 11b; C: CCL2; D: CCL5; E: TNFα; F: IL-1β). Samples w
sham animals plus corresponding contralateral regions (Sham N2 n = 9; Sha
as mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001.hemispheres were furthermore set in relation to their corre-
sponding contralateral hemispheres.
The primer sequences and further information about
the transcripts we analyzed is given in Table 1. We se-
lected the transcripts for analysis as follows: Argon was
found to have effects on both glial and neuronal cells, and
it only slightly attenuated LPS-induced production of cy-
tokines IL-1β, TNFα and IL-6 in a microgial cell line [12].
HIF-1α was found to be induced in xenon but not in
argon renal cell protection [18]. Since knowledge about
argon effects is in general very limited, additional factors
that are released by neuronal or glial or invading immune
cells and are furthermore associated with damage and/or
repair following neurotrauma were chosen for analysis.different inflammatory genes measured by RT-PCR are shown in
ere taken from the penumbra in tMCAO or corresponding region in
m Ar n = 8; tMCAO N2 n = 12; tMCAO n = 12). All values are presented
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In deep anesthesia, rats were transcardially perfused with
2% (w/v) paraformaldehyde (Roth, Germany) containing
15% (v/v) saturated picric acid at pH 7.4 (AppliedChem,
Germany). Brains were removed, kept in the same fixative
overnight and paraffin-embedded the next day (Merck,
Germany). Coronary sections (slices 3 and 5) of 5 μm thick-
ness were prepared, mounted on glass slides and rehydrated
using standard protocols. To verify infarction (MCAO) or
integrity (Sham), sections were stained with hematoxylin/
eosin (HE) using a standard protocol (Exemplary pictures
are presented in Figure 1B). For IHC, sections were incu-
bated with blocking serum for 1 h at room temperature,
following exposure to primary antibodies overnight (anti-
NeuN (1:500, Abcam, Cambridge, UK), anti-GFAP (1:1000,
Abcam, Cambridge, UK), and anti-ionized calcium-binding
adaptor molecule 1 (Iba1, 1:250, Wako, Osaka, Japan). After
several washing steps, sections were incubated with biotin-
conjugated secondary antibody for 1 h, and subsequently
with a biotin–avidin–enzyme complex (Vectastain ABC kit,
Vector Laboratories, Burlingame, USA). Antibody binding
was visualized by substrate incubation (AEC Substrate kit,
Invitrogen, Camarillo, USA). To quantify vital cells, stand-
ard light microscopy with a 20× objective lens was per-
formed and images were taken of three defined regions
(healthy cortex, cortex penumbra and ischemic core, see
Figure 1B) in the infarcted hemisphere and of correspond-
ing contralateral regions with a standard digital camera.Figure 3 Expression levels of further factors involved in post-ischemi
involved in post-ischemic inflammation and repair processes measured by
Samples were taken from the penumbra in tMCAO or corresponding regio
n = 9; Sham Ar n = 8; tMCAO N2 n = 12; tMCAO n = 12). All values are preseVital neurons (NeuN positive cells with a vital large light
caryon without shrinked/dense apperance), astrocytes
(GFAP-positive cells with minimum three branches) and
microglia (Iba1-positive cells with minimum two rami)
were analyzed with the help of a cell count software (Ima-
geJ, http://rsbweb.nih.gov/ij/) by two independent exam-
iners blinded to the treatment.
Statistics
Parametric data were evaluated by oneway ANOVA,
followed by post-hoc Newman-Keuls-testing for statis-
tical significance. GraphPad PRISM (GraphPad Software
Inc., La Jolla, California, USA) was used to calculate the
statistics and generate the figures. All values are given as
means ± SEM. A p-value ≤ 0.05 was considered statistically
significant.
Results
Expression of inflammatory genes
Expression of the cell marker protein CD3 was signifi-
cantly higher in the penumbra of tMCAO + placebo ani-
mals compared to tMCAO + argon or sham (Figure 2A).
Chemokine CCL2-expression levels were significantly
elevated in both tMCAO (+argon/+placebo) groups in
comparison to sham, with no significant difference be-
tween tMCAO groups (Figure 2C). Interleukines’ IL-1β
and IL-6 expression was significantly elevated in the
penumbra of the tMCAO + argon group compared toc inflammation and repair. Expression levels of different factors
RT-PCR are shown in Figure 3 (A: IL-6; B: HIF-1α; C: iNOS; D: MMP9).
n in sham animals plus corresponding contralateral regions (Sham N2
nted as mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001.
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p < 0.05; IL-6: 1.7 fold increase of induction, p < 0.05;
Figure 2F, 3A). IL-1β and IL-6 expression was significantly
elevated in tMCAO+ argon but not in tMCAO+ placebo
penumbra compared to the sham animals (Figure 2F, 3A).
The same was found for iNOS expression, which was
significantly induced in the penumbra of the tMCAO+
argon group (3.5 fold increase of induction compared to
tMCAO+ placebo, p < 0.001), but not in the penumbra of
the tMCAO+ placebo group (Figure 3C) compared to the
sham animals. CD11b, CCL5 and TNFα expression levels
were not significantly elevated at 24 h following cerebral in-
farction compared to healthy controls (Figures 2, B, D, E).
The expression of matrix metalloproteinase-9 (MMP-9)
and hypoxia inducible factor (HIF)-1α were significantly
higher in the penumbra following cerebral ischemiaFigure 4 Expression levels of repair and growth factors. Expression lev
differentiation and measured by RT-PCR are shown in Figure 4 (A: CNP; B:
the penumbra in tMCAO or corresponding region in sham animals plus co
tMCAO N2 n = 12; tMCAO n = 12). All values are presented as mean ± SEM.compared to healthy controls, with no significant differ-
ence between tMCAO + argon and tMCAO + placebo
(Figures 3B, D).
Expression of growth factors
The expression levels of 2',3'-cyclic-nucleotide 3'-phospho-
diesterase (CNP), glial fibrillary acid protein (GFAP), and
insulin-like growth factor (IGF)-1 were not affected 24 h
after the intervention in the different study groups
(Figures 4A, B, F). A significant upregulation of transform-
ing growth factor (TGF)-β, and neuronal growth factor
(NGF) mRNA-levels was found in the penumbra 24 h
following tMCAO+ argon treatment compared with
tMCAO+ placebo (TGF-β: 1.7 fold increase of induction,
p < 0.01; NGF: 1.5 fold increase of induction, p < 0.05;
Figures 4C, E). TGF-β and NGF expression was foundels of different growth factor genes involved in cerebral cell
GFAP; C: NGFb; D: VEGF; E: TGF β; F: IGF-1). Samples were taken from
rresponding contralateral regions (Sham N2 n = 9; Sham Ar n = 8;
*p < 0.05; **p < 0.01; ***p < 0.001.
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tMCAO+ placebo penumbra when compared to sham
(Figures 4C, E). Argon treatment following tMCAO fur-
ther led to a significantly increased expression of vascular
endothelial growth factor (VEGF)α in the penumbra com-
pared to sham, but not to tMCAO+ placebo (Figure 4D).
Distribution of neurons, microglia, and astrocytes
Neu-N staining
24 h following tMCAO versus sham surgery, numbers of
vital neurons in the healthy contralateral hemispheres were
comparable in all study groups (data not shown). In the is-
chemic core of the infarcted hemispheres, vital neurons
were significantly reduced following tMCAO+ placebo
(Figure 5A) when compared to healthy ipsilateral regions or
healthy tMCAO+ argon. No significant differences wereFigure 5 Cell numbers of neurons, astrocytes and microglia in
healthy cortex, penumbra and ischemic core region. The
numbers of neurons (A), microglia (B) and astrocytes (C)
differentiated by immunohistochemical staining in healthy ipsilateral
cortex (healthy), penumbra (penumbra) and ischemic core (ischemia)
of tMCAO animals and their corresponding sham regions are shown
in Figure 5. (Sham N2 n = 3; Sham Ar n = 3; tMCAO N2 n = 3; tMCAO
n = 3). All values are presented as mean ± SEM. * p < 0.05.found between tMCAO+ argon healthy and ischemic tis-
sue, or between tMCAO+ placebo and tMCAO+ argon
penumbra or ischemic core (Figure 5A). Example stainings
are shown in Figure 6A.
Iba-1 staining
Microglia counts were comparable in healthy contralateral
hemispheres in all study groups (data not shown). Micro-
glia numbers were not significantly different among treat-
ment groups neither in the ischemic nor in the penumbra
or healthy region (Figure 5B). Example stainings are shown
in Figure 6B.
GFAP-staining
Astrocyte numbers were not significantly different among
treatment groups neither in the ischemic (Figure 5C) nor
in the contralateral hemispheres (data not shown). Ex-
ample stainings are shown in Figure 6C.
Discussion
Recent experimental studies were able to demonstrate neu-
roprotective properties of argon in different ischemic and
traumatic settings [6-10,19]. However, cellular and molecu-
lar processes leading to this neuroprotection are largely un-
known. With this study, we intended to start elucidating
protective mechanisms of argon treatment in a model of
transient focal cerebral ischemia in rats. We identified sev-
eral genes whose transcription was elevated 24 h after inter-
vention, and whose expression levels significantly differed
between argon treatment and placebo following tMCAO.
Apart from the ischemic core in tMCAO+ placebo ani-
mals, numbers of astrocytes, microglia and neurons were
not significantly different in the study groups.
Following tMCAO+ argon, several inflammatory markers
showed significantly higher expression levels in the argon
group at 24 h post interventionem. The cytokines IL-1β
and IL-6 are regularly secreted by neurons and glia in re-
sponse to an ischemic stimulus and are involved in macro-
phage attraction and binding [20]. Especially IL-1β is
actively produced and released in stroke in tattered neurons
and activated microglia by activation of inflammasomes
and apoptotic pathways in the hypoxic brain. These differ-
ences in gene expression seem contradictory to the neuro-
protective effects exerted by argon in tMCAO in rats [10].
The cytokines have mostly been found to aggravate tissue
damage in ischemia [20-22]. IL-6 has also been attributed a
protective role [23,24]. About both the underlying patho-
mechanisms and the prospects of these unexpected results
we may only speculate. Direct as well as subordinate effects
of argon on the injured tissue might be underlying these
findings. Of note, expression kinetics of these cytokines
showed an immediate up-regulation approximately one to
two hours after brain injury induction with peak levels after
6 to 12 h [25,26]. Since in our study mRNA levels were
Figure 6 Immunhistochemical stainings of neurons, astrocytes and microglia in healthy cortex, penumbra and ischemic core region.
Example pictures of neurons (NeuN staining, A), microglia (Iba-1 staining, B) and astrocytes (GFAP staining C) taken from healthy ipsilateral cortex
(h), penumbra (p) and ischemic core (c) of tMCAO animals and their corresponding sham regions are shown in Figure 6. (Sham N2 n = 3; Sham Ar
n = 3; tMCAO N2 n = 3; tMCAO n = 3).
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thinkable that besides a prolonged upregulation of these cy-
tokines, argon might induce a delay of mRNA-expression
which might effect a shift of peak expression to a later time
point. At 24 h post-ischemia the elevated expression of
iNOS, whose role in ischemic brain damage and repair isstill discussed [27,28], might also be due to altered cyto-
kine kinetics. Another important point to consider is that
the timing of sampling might contribute to these confus-
ing results. Only having the 24-hour snap shot might not
be sufficient to draw mechanistic conclusions. Both earlier
(first 6-to-12 hours of post-ischemia) and later (48 hours
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ther studies to examine these seemingly controversial re-
sults and their link to tissue protection.
Growth factors are involved in initiation of repair mech-
anisms to organize tissue damage and initiate cell migra-
tion and differentiation. TGF-β-expression was found to
be elevated 24 h after tMCAO+ argon while it was not af-
fected by tMCAO+ placebo. TGF-β is associated with
profound neuroprotective activities [29,30]. NGF, which
was also induced by argon treatment in our study, has
been shown to exert neuroprotective properties partly via
an antiapoptotic mechanism [31]. VEGFα plays a role in
regulation of cerebral blood flow and angiogenesis and
thereby is proposed to act as a neuroprotectant [32]. The
fact that these neuroprotective factors were increased fol-
lowing argon therapy might contribute to its beneficial
effects [10].
Tissue protection by xenon preconditioning and treat-
ment has been associated with an up-regulation of HIF-1α
in several in vivo and in vitro models of ischemia [18,33,34].
Argon preconditioning did not induce HIF-1α in renal is-
chemia in vitro, but also lacked protective effects in this ex-
periment [18]. In our study, we did not find an upregulated
expression of HIF-1α following argon treatment of tMCAO
induced cerebral ischemia despite of it’s neuroprotective ef-
fects [10]. Whether the missing induction of HIF-1α is spe-
cific to argon, or due to other reasons (timing of treatment,
examination time) will have to be determined elsewhere.
Still, some open questions remain: There was no sta-
tistically significant difference in neuron numbers be-
tween tMCAO + argon and tMCAO + placebo in the
penumbra, although behavioural scoring and cortical in-
farct volumes in tMCAO + argon animals had been im-
proved compared to placebo treatment [10]. A higher
number of animals might be required to establish such a
correlation. Alternatively, the reason for this finding
could be that the behavioural scoring does not reflect
the neuronal situation in the penumbra. Furthermore,
we found several notable changes in the expression of
the above named genes, but their exact cellular source
remains to be identified. Additional studies will have to
address these questions.Conclusion
In our study, we found controversial results. Besides el-
evated expressions of several inflammatory cytokines
(IL-1β, IL-6, iNOS) we found an increased expression of
neuroprotective growth factors (TGFβ, NGF, VEGF) fol-
lowing tMCAO + argon compared to tMCAO + placebo.
These findings might be associated with the previously
described neuroprotective effects of argon following ex-
perimental neurotrauma. Further studies will have to
evaluate the relevance of these findings.Competing interests
MC and RR received lecture and consultant fees from Air Liquide Santé
International, a company interested in developing clinical applications for
medical gases, including argon and xenon. AVF received a travel recompensation
for an investigators meeting from Air Liquide Santé International. All other
authors declare that they have no competing interests.
Authors’ contributions
YMR conducted the animal experiments. AVF, AP and NG conducted the
laboratory experimental work. JG and HH performed the histological
evaluation and helped to draw the manuscript. YMR and AVF performed the
statistical analysis and drafted the manuscript. RR, MC, and CB participated in
the study design and coordination and helped to draft the manuscript. All
authors read and approved the final manuscript.
Acknowledgements
We thank the team at the Department of Animal Research, University
Hospital Aachen for expert laboratory advice, assistance and help. We further
thank J. Hoffmann and R. Debarry for their excellent technical assistance.
Funding
This research was conducted with funding by the Rotationsprogramm (YMR, AVF)
and the START programm (AVF), both Medical Faculty, RWTH Aachen.
Author details
1Department of Anesthesiology, University Hospital RWTH, Pauwelsstr. 30,
Aachen 52074, Germany. 2Department of Neurosurgery, Klinikum rechts der
Isar, Technische Universität, München, Germany. 3Institute of Neuroanatomy,
Faculty of Medicine, RWTH, Aachen, Germany. 4Institute of Immunology,
University Hospital RWTH, Aachen, Germany.
Received: 23 April 2014 Accepted: 29 May 2014
Published: 6 June 2014
References
1. Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM,
Khatri P, McMullan PW Jr, Qureshi AI, Rosenfield K, Scott PA, Summers DR,
Wang DZ, Wintermark M, Yonas H, American Heart Association Stroke
Council; Council on Cardiovascular Nursing; Council on Peripheral Vascular
Disease; Council on Clinical Cardiology: Guidelines for the early
management of patients with acute ischemic stroke: a guideline for
healthcare professionals from the American Heart Association/American
Stroke Association. Stroke 2013, 44:870–-947.
2. The European Stroke Organisation (ESO) Executive Committee and the ESO
Writing Committee: Guidelines for Management of Ischaemic Stroke and
Transient Ischaemic Attack 2008. Cerebrovasc Dis 2008, 25:457–507.
3. Bandera E, Botteri M, Minelli C, Sutton A, Abrams KR, Latronico N: Cerebral
blood flow threshold of ischemic penumbra and infarct core in acute
ischemic stroke: a systematic review. Stroke 2006, 37:1334–1339.
4. Dickinson R, Franks NP: Bench-to-bedside review: Molecular
pharmacology and clinical use of inert gases in anesthesia and
neuroprotection. Crit Care 2010, 14:229.
5. Sheng SP, Lei B, James ML, Lascola CD, Venkatraman TN, Jung JY, Maze M,
Franks NP, Pearlstein RD, Sheng H, Warner DS: Xenon neuroprotection in
experimental stroke: interactions with hypothermia and intracerebral
hemorrhage. Anesthesiology 2012, 117:1262–1275.
6. Brücken A, Cizen A, Fera C, Meinhardt A, Weis J, Nolte K, Rossaint R, Pufe T,
Marx G, Fries M: Argon reduces neurohistopathological damage and
preserves functional recovery after cardiac arrest in rats. Br J Anaesth
2013, 110(Suppl 1):i106–i112.
7. Zhuang L, Yang T, Zhao H, Fidalgo AR, Vizcaychipi MP, Sanders RD, Yu B,
Takata M, Johnson MR, Ma D: The protective profile of argon, helium, and
xenon in a model of neonatal asphyxia in rats. Crit Care Med 2012,
40:1724–1730.
8. David HN, Haelewyn B, Degoulet M, Colomb DG Jr, Risso JJ, Abraini JH: Ex
vivo and in vivo neuroprotection induced by argon when given after an
excitotoxic or ischemic insult. PLoS One 2012, 7:e30934.
9. Harris K, Armstrong SP, Campos-Pires R, Kiru L, Franks NP, Dickinson R: Neu-
roprotection against traumatic brain injury by xenon, but not argon, is
mediated by inhibition at the N-methyl-D-aspartate receptor glycine site.
Anesthesiology 2013, 119:1137–1148.
Fahlenkamp et al. Medical Gas Research 2014, 4:11 Page 11 of 11
http://www.medicalgasresearch.com/content/4/1/1110. Ryang YM, Fahlenkamp AV, Rossaint R, Wesp D, Loetscher PD, Beyer C,
Coburn M: Neuroprotective effects of argon in an in vivo model of
transient middle cerebral artery occlusion in rats. Crit Care Med 2011,
39:1448–1453.
11. Behnke AR, Yarbrough OD: Respiratory resistance, oil-water solubility, and
mental effects of argon, compared with helium and nitrogen. Am J
Physiol 1939, 126:409–415.
12. Fahlenkamp AV, Rossaint R, Haase H, Al Kassam H, Ryang YM, Beyer C,
Coburn M: The noble gas argon modifies extracellular signal-regulated
kinase 1/2 signaling in neurons and glial cells. Eur J Pharmacol 2012,
674:104–111.
13. Koizumi J, Yoshida Y, Nakazawa T, Ooneda G: Experimental studies of
ischemic brain edema: I: A new experimental model of cerebral
embolism in which recirculation can be introduced into the ischemic
area. Jpn J Stroke 1986, 8:1–8.
14. Bederson JB, Pitts LH, Tsuji M, Nishimura MC, Davis RL, Bartkowski H: Rat
middle cerebral artery occlusion: evaluation of the model and
development of a neurologic examination. Stroke 1986, 17:472–476.
15. Bederson JB, Pitts LH, Germano SM, Nishimura MC, Davis RL, Bartkowski HM:
Evaluation of 2,3,5-triphenyltetrazolium chloride as a stain for detection
and quantification of experimental cerebral infarction in rats. Stroke 1986,
17:1304–1308.
16. Kramer M, Dang J, Baertling F, Denecke B, Clarner T, Kirsch C, Beyer C, Kipp M:
TTC staining of damaged brain areas after MCA occlusion in the rat does
not constrict quantitative gene and protein analyses. J Neurosci Methods
2010, 187:84–89.
17. Swanson RA, Morton MT, Tsao-Wu G, Savalos RA, Davidson C, Sharp FR: A
semiautomated method for measuring brain infarct volume. J Cereb
Blood Flow Metab 1990, 10:290–293.
18. Rizvi M, Jawad N, Li Y, Vizcaychipi MP, Maze M, Ma D: Effect of noble gases
on oxygen and glucose deprived injury in human tubular kidney cells.
Exp Biol Med (Maywood) 2010, 235:886–891.
19. Loetscher PD, Rossaint J, Rossaint R, Weis J, Fries M, Fahlenkamp A, Ryang YM,
Grottke O, Coburn M: Argon: neuroprotection in in vitro models of cerebral
ischemia and traumatic brain injury. Crit Care 2009, 13:R206.
20. Huang J, Upadhyay UM, Tamargo RJ: Inflammation in stroke and focal
cerebral ischemia. Surg Neurol 2006, 66:232–245.
21. Denes A, Pinteaux E, Rothwell NJ, Allan SM: Interleukin-1 and stroke:
biomarker, harbinger of damage, and therapeutic target. Cerebrovasc Dis
2011, 32:517–527.
22. Tarkowski E, Rosengren L, Blomstrand C, Wikkelso C, Jensen C, Ekholm S,
Tarkowski A: Early intrathecal production of interleukin-6 predicts the size
of brain lesion in stroke. Stroke 1995, 26:1393–1398.
23. Tilg H, Trehu E, Atkins MB, Dinarello CA, Mier JW: Interleukin-6 (IL-6) as an
anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist
and soluble tumor necrosis factor receptor p55. Blood 1994, 83:113–118.
24. Ali C, Nicole O, Docagne F, Lesne S, MacKenzie ET, Nouvelot A, Buisson A,
Vivien D: Ischemia-induced interleukin-6 as a potential endogenous neu-
roprotective cytokine against NMDA receptor-mediated excitotoxicity in
the brain. J Cereb Blood Flow Metab 2000, 20:956–966.
25. Wang X, Yue TL, Young PR, Barone FC, Feuerstein GZ: Expression of
interleukin-6, c-fos, and zif268 mRNAs in rat ischemic cortex. J Cereb
Blood Flow Metab 1995, 15:166–171.
26. Wang X, Yue TL, Barone FC, White RF, Gagnon RC, Feuerstein GZ:
Concomitant cortical expression of TNF-alpha and IL-1 beta mRNAs
follows early response gene expression in transient focal ischemia.
Mol Chem Neuropathol 1994, 23:103–114.
27. Prüss H, Prass K, Ghaeni L, Milosevic M, Muselmann C, Freyer D, Royl G,
Reuter U, Baeva N, Dirnagl U, Meisel A, Priller J: Inducible nitric oxide
synthase does not mediate brain damage after transient focal cerebral
ischemia in mice. J Cereb Blood Flow Metab 2008, 28:526–539.
28. Kidd GA, Hong H, Majid A, Kaufman DI, Chen AF: Inhibition of brain GTP
cyclohydrolase I and tetrahydrobiopterin attenuates cerebral infarction
via reducing inducible NO synthase and peroxynitrite in ischemic stroke.
Stroke 2005, 36:2705–2711.
29. Ruocco A, Nicole O, Docagne F, Ali C, Chazalviel L, Komesli S, Yablonsky F,
Roussel S, MacKenzie ET, Vivien D, Hbuissob A: A transforming growth
factor-beta antagonist unmasks the neuroprotective role of this en-
dogenous cytokine in excitoxic and ischemic brain injury. J Cereb Blood
Flow Metab 1999, 19:1345–1353.30. Dhandapani KM, Brann DW: Transforming growth factor-beta: a neuropro-
tective factor in cerebral ischemia. Cell Biochem Biophys 2003, 39:13–22.
31. Yang JP, Liu HJ, Yang H, Feng PY: Therapeutic time window for the
neuroprotective effects of NGF when administered after focal cerebral
ischemia. Neurol Sci 2011, 32:433–441.
32. Yang J, Guo L, Liu R, Liu H: Neuroprotective effects of VEGF
administration after focal cerebral ischemia/reperfusion: dose response
and time window. Neurochem Int 2012, 60:592–596.
33. Limatola V, Ward P, Cattano D, Gu J, Giunta F, Maze M, Ma D: Xenon
preconditioning confers neuroprotection regardless of gender in a
mouse model of transient middle cerebral artery occlusion.
Neuroscience 2010, 165:874–881.
34. Zhao H, Watts HR, Chong M, Huang H, Tralau-Stewart C, Maxwell PH, Maze M,
George AJ, Ma D: Xenon treatment protects against cold ischemia associated
delayed graft function and prolongs graft survival in rats. Am J Transplant
2013, 13:2006–2018.
doi:10.1186/2045-9912-4-11
Cite this article as: Fahlenkamp et al.: Expression analysis following
argon treatment in an in vivo model of transient middle cerebral artery
occlusion in rats. Medical Gas Research 2014 4:11.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
